Analyst Michael Matson of Needham reiterated a Buy rating on Penumbra, retaining the price target of $326.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors that highlight Penumbra’s strong financial performance and strategic advancements. The company’s third-quarter revenue and earnings per share exceeded market expectations, prompting an upward revision of their 2025 revenue guidance. Notably, there was significant growth in their Thrombectomy and Embolization and Access segments, indicating robust demand and operational efficiency.
Additionally, Penumbra’s efforts to improve margins have been successful, with both gross and operating margins showing year-over-year improvements. The management’s proactive approach in addressing regulatory queries related to their Thunderbolt 510(k) application has also been a positive development, alleviating investor concerns. Their excitement about introducing new technologies to the neurovascular field further supports the optimistic outlook, reinforcing the Buy rating.
Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, Penumbra, and TransMedics Group. According to TipRanks, Matson has an average return of -2.5% and a 39.96% success rate on recommended stocks.
In another report released today, TR | OpenAI – 4o also upgraded the stock to a Buy with a $259.00 price target.